Last reviewed · How we verify
Enarodustat 2mg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Enarodustat 2mg (Enarodustat 2mg) — Shenzhen Salubris Pharmaceuticals Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Enarodustat 2mg TARGET | Enarodustat 2mg | Shenzhen Salubris Pharmaceuticals Co., Ltd. | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Enarodustat 2mg CI watch — RSS
- Enarodustat 2mg CI watch — Atom
- Enarodustat 2mg CI watch — JSON
- Enarodustat 2mg alone — RSS
Cite this brief
Drug Landscape (2026). Enarodustat 2mg — Competitive Intelligence Brief. https://druglandscape.com/ci/enarodustat-2mg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing